to see a very optimistic view of vanda 's iloperidone , read an article at the red herring here 's a snippet thomas weisel analyst donald ellis agrees that vanda is superior to other atypical antipsychotic drugs because of its less frequent incidence of side effects iloperidone is differentiated from existing atypical antipsychotics because of a lower incidence of weight gain , diabetes , extrapyramidal symptoms involuntary body movements , sedation and impaired cognition we believe vanda is well positioned for a potential acquisition by a major pharmaceutical company , he wrote in a research note and with the sales of atypical antipsychotics reaching billion in , a percent increase from , iloperidone looks to be a great boon for vanda bank of america analyst maris projects that iloperidone will garner million in sales for vanda by after the successful results of this trial , vanda will likely file for a new drug application with the fda in and launch sales of iloperidone in iloperidone looks to have a very attractive safety profile , he writes the very attractive safety profile line is used prior to the release of nearly every new medication , though the actual safety profile , as we 've seen with the current lineup of atypical antipsychotics , is a different story maybe i'm wrong and iloperidone , despite languishing for years in development and having not a single publicly available efficacy trial , is the next big thing for schizophrenia more on iloperidone here